Translational and Clinical Science

Jan 13, 2025

The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical and Translational Science

Nov 14, 2023

NIMML Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

Oct 23, 2023

NIMML Announces Positive Results of Omilancor Clinical Trials in Ulcerative Colitis and Crohn’s Disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

Jul 13, 2023

The NIMML Institute Announces Publication of a Study in Inflammatory Bowel Diseases

May 17, 2023

NIMML Institute's TITAN-X Drug Development Platform Empowers NImmune Biopharma's Global Pivotal Phase 3 Clinical Trials for Omilancor in Ulcerative Colitis

< Previous